Advertisement

Topics

Arcus Biosciences Company Profile

08:06 EDT 26th May 2018 | BioPortfolio

Arcus Biosciences (“Arcus”) is a biotechnology company focused on the discovery and development of innovative cancer immunotherapies. Arcus was founded in 2015 by Terry Rosen and Juan Jaen, the co-founders of Flexus Biosciences, which in February 2015 was acquired by Bristol-Myers Squibb to access Flexus’s IDO inhibitor, which was in preclinical development at the time and is now referred to as BMS-986205. Arcus has several programs targeting important immuno-oncology pathways, including a first-in-class dual adenosine receptor antagonist and a PD-1 antibody, both of which are about to enter phase 1 studies, as well as a first-in-class small molecule inhibitor of CD73 and a TIGIT antibody, which are in IND-enabling studies. Arcus has over 70 employees with extensive expertise in medicinal chemistry, immunology, biochemistry, pharmacology, and structural biology. To date, Arcus has raised $120mm in funding from investors including GV (previously known as Google Ventures), Foresite Capital, The Column Group, Invus LP, Novartis, Celgene, Taiho Ventures, Stanford University, and DROIA, as well as from senior management. The company is based in Hayward, CA.


News Articles [623 Associated News Articles listed on BioPortfolio]

#news #biotech Arcus Biosciences eyes $100M IPO

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Arcus Biosciences eyes $100M IPO .Mere months after bagging $107 million in i...

Arcus Biosciences files for IPO

Arcus Biosciences Inc. (cancer immunotherapies) filed for its initial public offering.

Arcus Biosciences nets $111.6mm in IPO

Arcus Biosciences Inc. (cancer immunotherapies) netted $111.6mm through its initial public offering of 8mm common shares priced at $15; the company had originally intended to sell 7.1mm shares at a ra...

Arcus Bio Pulls Off IPO, Raises $120M for Cancer Immunotherapies

Arcus Biosciences has raised $120 million from an initial public offering as the cancer immunotherapy developer looks ahead to reporting its first clinical data for its two lead drugs later this year....

Arcus Biosciences Announces Five Abstracts Accepted for Presentation at AACR 2018 Annual Meeting

Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that five abstracts have been acc...

Arcus Biosciences Announces Pricing of Initial Public Offering

Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the pricing of its initial public...

Arcus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the closing of its initial p...

IPO raises $120M for cancer immunotherapy developer

An initial public offering brought in $120 million for cancer immunotherapy developer Arcus Biosciences.  -More- 

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [71 Associated PubMed Articles listed on BioPortfolio]

Familial Hypercholesterolemia: Xanthelasma, Corneal Arcus and Tendon Xanthomas, only in severe forms.

Draft Genome Sequences of Trichophyton rubrum CMCC(F)T1i and Trichophyton violaceum CMCC(F)T3l by Illumina 2000 and Pacific Biosciences.

One strain of Trichophyton rubrum CMCC(F)T1i (=CBS 139224) isolated from onychomycosis and one strain of Trichophyton violaceum CMCC(F)T3l (=CBS 141829) isolated from tinea capitis in China were whole...

Introduction.

Back cover.

Contents list.

Clinical Trials [9 Associated Clinical Trials listed on BioPortfolio]

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic

The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudom...

Companies [350 Associated Companies listed on BioPortfolio]

Arcus Biosciences, Inc.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncolo...

Arcus Biosciences

Arcus Biosciences (“Arcus”) is a biotechnology company focused on the discovery and development of innovative cancer immunotherapies. Arcus was founded in 2015 by Ter...

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. (formerly Sigma-Tau Pharmaceuticals, Inc.) is a U.S.-based, wholly owned subsidiary of Leadiant Biosciences S.p.A., a research-based pharmaceutical comp...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

More Information about "Arcus Biosciences" on BioPortfolio

We have published hundreds of Arcus Biosciences news stories on BioPortfolio along with dozens of Arcus Biosciences Clinical Trials and PubMed Articles about Arcus Biosciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Arcus Biosciences Companies in our database. You can also find out about relevant Arcus Biosciences Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record